These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
318 related articles for article (PubMed ID: 35278204)
21. Explaining biosimilars and how reverse engineering plays a critical role in their development. Bellinvia S; Edwards CJ Expert Opin Drug Discov; 2020 Nov; 15(11):1283-1289. PubMed ID: 32717155 [TBL] [Abstract][Full Text] [Related]
22. Biosimilars: Practical Considerations for Pharmacists. Stevenson JG; Popovian R; Jacobs I; Hurst S; Shane LG Ann Pharmacother; 2017 Jul; 51(7):590-602. PubMed ID: 28176529 [TBL] [Abstract][Full Text] [Related]
23. Biosimilars: A consideration of the regulations in the United States and European union. Daller J Regul Toxicol Pharmacol; 2016 Apr; 76():199-208. PubMed ID: 26732800 [TBL] [Abstract][Full Text] [Related]
24. [Biosimilars in oncology: a therapeutic alternative to the reference products?]. Ludwig WD; Dicheva S Z Gastroenterol; 2016 Nov; 54(11):1223-1229. PubMed ID: 27723912 [TBL] [Abstract][Full Text] [Related]
25. Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective. Kurki P; Barry S; Bourges I; Tsantili P; Wolff-Holz E Drugs; 2021 Nov; 81(16):1881-1896. PubMed ID: 34596876 [TBL] [Abstract][Full Text] [Related]
26. The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA. Gherghescu I; Delgado-Charro MB Pharmaceutics; 2020 Dec; 13(1):. PubMed ID: 33396369 [TBL] [Abstract][Full Text] [Related]
27. An Update Review of Biosimilars of Adalimumab in Psoriasis - Bioequivalence and Interchangeability. Zhou X; Chen Z; Bi X Drug Des Devel Ther; 2021; 15():2987-2998. PubMed ID: 34267501 [TBL] [Abstract][Full Text] [Related]
28. Clinical and Regulatory Considerations for the Use of Bevacizumab Biosimilars in Metastatic Colorectal Cancer. Taïeb J; Aranda E; Raouf S; Dunn H; Arnold D Clin Colorectal Cancer; 2021 Mar; 20(1):42-51.e3. PubMed ID: 33243618 [TBL] [Abstract][Full Text] [Related]
29. [Opportunities and challenges of extrapolation for biosimilars]. Weise M; Wolff-Holz E Z Gastroenterol; 2016 Nov; 54(11):1211-1216. PubMed ID: 27711947 [TBL] [Abstract][Full Text] [Related]
30. [Biosimilars in the European Union: current situation and challenges]. Wolff-Holz E; Weise M Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2020 Nov; 63(11):1365-1372. PubMed ID: 33034693 [TBL] [Abstract][Full Text] [Related]
32. Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions. Bennett CL; Schoen MW; Hoque S; Witherspoon BJ; Aboulafia DM; Hwang CS; Ray P; Yarnold PR; Chen BK; Schooley B; Taylor MA; Wyatt MD; Hrushesky WJ; Yang YT Lancet Oncol; 2020 Dec; 21(12):e575-e588. PubMed ID: 33271114 [TBL] [Abstract][Full Text] [Related]
33. Drug Development and Potential Regulatory Paths for Insulin Biosimilars. Minocha M; Gobburu J J Diabetes Sci Technol; 2014 Jan; 8(1):14-19. PubMed ID: 24876531 [TBL] [Abstract][Full Text] [Related]
34. Biosimilar medicines uptake: The role of the clinical pharmacist. Okoro RN Explor Res Clin Soc Pharm; 2021 Mar; 1():100008. PubMed ID: 35479506 [TBL] [Abstract][Full Text] [Related]
35. Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology. Mysler E; Pineda C; Horiuchi T; Singh E; Mahgoub E; Coindreau J; Jacobs I Rheumatol Int; 2016 May; 36(5):613-25. PubMed ID: 26920148 [TBL] [Abstract][Full Text] [Related]
36. Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction. Ingrasciotta Y; Cutroneo PM; Marcianò I; Giezen T; Atzeni F; Trifirò G Drug Saf; 2018 Nov; 41(11):1013-1022. PubMed ID: 29796832 [TBL] [Abstract][Full Text] [Related]